Patient baseline characteristics
| Characteristic . | N = 40 . |
|---|---|
| Median age (range), y | 69 (52-83) |
| Sex, male/female | 35/5 |
| WHO PS score, n (%) | |
| 0 | 14 (35.0) |
| 1 | 21 (52.5) |
| 2 | 4 (10.0) |
| Missing | 1 (2.5) |
| MIPI score, n (%) | |
| Low (<5.7) | 10 (25) |
| Intermediate (5.7-6.2) | 16 (40) |
| High (>6.2) | 14 (35) |
| Risk factors, n (%) | |
| Age >60 y | 35 (88) |
| WHO PS ≥2 | 4 (10) |
| LDH >ULN | 18 (45) |
| WBC >ULN | 6 (15) |
Bulky disease (>5 cm) | 24 (60) |
Treatment history | |
| Median number of prior therapies (range) | 4 (1-14) |
| ≥6 regimens, n (%) | 13 (32) |
| Prior therapy type, n (%) | |
| Rituximab | 40 (100) |
| Alkylating agent | 39 (98) |
| Anthracycline | 35 (88) |
| Bortezomib | 24 (60) |
| Bendamustine | 12 (40) |
| Autologous stem cell transplantation | 9 (22) |
| Purine analog | 9 (23) |
| Lenalidomide | 8 (20) |
| Refractory to last regimen, n (%) | 17 (43) |
| Characteristic . | N = 40 . |
|---|---|
| Median age (range), y | 69 (52-83) |
| Sex, male/female | 35/5 |
| WHO PS score, n (%) | |
| 0 | 14 (35.0) |
| 1 | 21 (52.5) |
| 2 | 4 (10.0) |
| Missing | 1 (2.5) |
| MIPI score, n (%) | |
| Low (<5.7) | 10 (25) |
| Intermediate (5.7-6.2) | 16 (40) |
| High (>6.2) | 14 (35) |
| Risk factors, n (%) | |
| Age >60 y | 35 (88) |
| WHO PS ≥2 | 4 (10) |
| LDH >ULN | 18 (45) |
| WBC >ULN | 6 (15) |
Bulky disease (>5 cm) | 24 (60) |
Treatment history | |
| Median number of prior therapies (range) | 4 (1-14) |
| ≥6 regimens, n (%) | 13 (32) |
| Prior therapy type, n (%) | |
| Rituximab | 40 (100) |
| Alkylating agent | 39 (98) |
| Anthracycline | 35 (88) |
| Bortezomib | 24 (60) |
| Bendamustine | 12 (40) |
| Autologous stem cell transplantation | 9 (22) |
| Purine analog | 9 (23) |
| Lenalidomide | 8 (20) |
| Refractory to last regimen, n (%) | 17 (43) |
LDH, lactic dehydrogenase; PS, performance status; ULN, upper limit of normal; WBC, white blood cell count; WHO, World Health Organization.